Big Pharma
19 December 2025 With its landmark ruling, the court has delivered guidance for patentees and litigants— including three takeaways for counsel and rights holders, explain Tobias Wuttke and Axel Berger of Bardehle Pagenberg.
18 December 2025
17 December 2025
16 December 2025
15 December 2025
11 December 2025
9 December 2025
Latest Features
Europe
The High Court’s ruling clarifies aspects of the SPC waiver but leaves unresolved questions relating to export-country rights and confidentiality, say Claire Phipps-Jones and Luke Norton of Bristows.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Europe
With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.
Big Pharma
Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
More News
2 December 2025 The move could unlock billions in life sciences collaborations and position the UK to rival the US and China. But turning a famously conservative, patient-safety-first institution into a commercially savvy innovation hub will be no small feat.
27 November 2025 Director Squires rescinds previous guidelines and clarifies that there is no separate, modified inventorship standard for AI-assisted inventions.
26 November 2025 Balancing tight budgets while keeping up with fast-changing biosimilar rules is all in a day’s work for Novartis’s R&D IP team, but how do they stay on top of it all?
21 November 2025 The week exposed fractures in the UK's industry—but also unexpected reasons for optimism. Five themes dominated conversations about the direction of the country's life sciences sector.
20 November 2025 The country’s public health service has replaced its IP framework with a nine-step plan, as the government tries to reposition the UK as a global life sciences leader.
20 November 2025 A PTAB dispute over $29.5bn drug reaches a dramatic conclusion, at a critical time ahead of the drug's US patent expiration.
20 November 2025 A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox